# Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

> **NCT04677569** · PHASE3 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 425 (actual)

## Conditions studied

- Mycobacterium Infections, Nontuberculous

## Interventions

- **DRUG:** ALIS
- **DRUG:** Azithromycin
- **DRUG:** Ethambutol
- **DRUG:** ELC (matching placebo for ALIS)

## Key facts

- **NCT ID:** NCT04677569
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2025-11-21
- **Final completion:** 2026-01-15
- **Target enrollment:** 425 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04677569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04677569, "Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04677569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*